The Placenta Previa and Fetal Weight
The Effect of Placenta Previa on Fetal Weight and Feto-maternal Blood Flow
1 other identifier
observational
200
0 countries
N/A
Brief Summary
Placenta previa is a placenta that implants at lower uterine segment, it occurs in about 0.3-0.5% of pregnancies at term. It is a significant risk for development of maternal morbidity, as well as maternal mortality secondary to maternal hemorrhage . Also, this abnormal placenta has a negative concern about fetal well being due to prematurity and perinatal mortality, in addition to its undesirable effect on fetal growth. Several factors may be behind of the effect of placenta previa on fetal growth. Firstly, the blood supply to the lower uterine segment is less than at the upper segment apparently resulting in less feto-placental blood perfusion . Secondly, recurrent bleeding attacks from placental previa may affect fetal oxygenation and fetal growth. In spite of above evidences; many studies in literature denied the relation between placenta previa and fetal growth and concluded that the association between low birth weight and placenta previa is mainly due to preterm delivery and to a lesser extent with fetal growth restriction. However; the major drawback of all these studies is lacking of reporting the effect of placenta previa of feto-maternal blood flow representing in studying of Doppler blood flow in both uterine and umbilical artery in those patients. The uterine artery blood flow is usually affected by the presence of placenta previa and placenta accreta which reflected on feto-placental blood flow. So the uterine artery Doppler velocimetry is a useful tool for predicting placenta accreta . So in the light of above evidences; we aimed, in the current study, not only to investigate the effect on placenta previa on fetal weight but also to walk around the effect of placenta previa on the uterine and umbilical arteries blood flow in trial to explore this conflicting issue. To our knowledge, no previous trial had studied this interesting subject before.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2016
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2017
CompletedFirst Submitted
Initial submission to the registry
October 21, 2017
CompletedFirst Posted
Study publicly available on registry
October 25, 2017
CompletedNovember 17, 2017
November 1, 2017
10 months
October 21, 2017
November 14, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Estimated fetal wight (gram)
4 weeks
Secondary Outcomes (1)
The value of Doppler indices in uterine artery
4 weeks
Study Arms (2)
placenta previa group
Normal control group
Interventions
women had placenta previa either major or minor degree
Eligibility Criteria
placenta previa patients
You may qualify if:
- Women who are sure of her pregnancy.
- Women aged 20-35 years.
- Women with BMI 18-22 kg/m2.
- Estimated gestational age is ranging between 30- 32 weeks gestation.
- Singleton pregnancy.
- Placenta previa; either major or minor degrees as regard the cases.
- Placenta previa with minimal vaginal bleeding or haven't any vaginal bleeding.
- Women with normal Doppler indices in uterine and umbilical arteries at time of recruitment.
- Women should be living in a nearby area to make follow-up and early transportation are reasonably possible.
You may not qualify if:
- Women aged \< 20 and \>35 years.
- Smoker ≥ 11 cigarettes/day.
- Severe attack of bleeding requiring an immediate intervention.
- Fetal heart rates instability or non reassuring.
- Multiple gestations.
- Previous Intrauterine growth restricted fetus.
- Intrauterine fetal death or major fetal anomalies.
- If associated with abruptio placentae.
- Patients with known bleeding disorders or on anticoagulant therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer
Study Record Dates
First Submitted
October 21, 2017
First Posted
October 25, 2017
Study Start
October 1, 2016
Primary Completion
August 1, 2017
Study Completion
October 1, 2017
Last Updated
November 17, 2017
Record last verified: 2017-11